Loading, Please Wait...
NEW YORK, NY --(Marketwired - March 24, 2016) - The Trout Group, the leading global investor relations and strategic advisory firm servicing the life sciences industry, today announced an upcoming Trout Talk key opinion leader (KOL) discussion featuring Leisha A. Emens, M.D., PhD, Associate Professor of Oncology at Johns Hopkins University School of Medicine. Dr. Emens Talk, Breast Cancer Vaccines, will focus on her work with breast GVAX. The Trout Talk will be webcast live on March 29 at 12 pm ET and can be accessed at trouttalk.troutgroup.com.
Trout Talks is an ongoing series featuring conversations with prominent and up-and-coming researchers who are driving scientific innovation forward.
Dr. Emens is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center where she and specializes in cancer immunotherapy. Her research focuses on the development and implementation of breast cancer immunotherapies (including vaccination strategies and immune checkpoint blockade) in combination with traditional anticancer therapies and newer biologically targeted therapies. She is a member of the FDA Advisory Committee on Cell, Tissue, and Gene Therapies, and on the editorial boards of the Journal of Clinical Oncology, Cancer Research, and the Journal for the Immunotherapy of Cancer.
Amongst other topics, Dr. Emens will discuss her work with breast GVAX, a vaccine that has already demonstrated safety and immune activity in in early trials. This year Dr. Emens, and co-investigator, Dr. Elizabeth Jaffee will combine GVAX with a newly developed immune adjuvant called STING to enhance immunity.
The Trout Talk, moderated by Trout Group scientific advisor Neil Canavan, will consist of a 1 hour presentation by Dr. Emens followed by up to 30 minutes of Q&A. Webcast participants can send questions to email@example.com at any time before or during the event; submitted questions will be answered in the order received, and the asker's identity shall remain anonymous.
About The Trout Group:
The Trout Group is a global investor relations and strategic advisory firm. Since 1996, Trout has been a leading strategic partner to the life sciences industry, connecting companies, the capital markets and innovations in the sector. Trout's unique suite of services at the intersection of scientific advances and a network of institutional relationships creates long term value for stakeholders.
For general inquires please contact: